Valuation PharmaEssentia Corporation LUXEMBOURG S.E.
Stocks
261280558
US7169721047
Biotechnology & Medical Research
|
End-of-day quote
LUXEMBOURG S.E.
14/08/2026
|
5-day change | 1st Jan Change | ||
| 47.00 USD | +4.44% |
|
+22.40% | +247.80% |
| 08-13 | PharmaEssentia Clarifies Report Projecting 2026 Revenue | MT |
| 08-12 | PharmaEssentia Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: PharmaEssentia Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 78,065 | 143,840 | 114,578 | 204,725 | 173,829 | 621,648 | - | - |
| Change | - | 84.26% | -20.34% | 78.68% | -15.09% | 257.62% | - | - |
| Enterprise Value (EV) 1 | 75,148 | 133,629 | 94,995 | 183,725 | 153,423 | 595,124 | 586,920 | 621,648 |
| Change | - | 77.82% | -28.91% | 93.4% | -16.49% | 287.9% | -1.38% | 5.92% |
| P/E | -27.1x | -98.6x | -179x | 69.3x | 34.6x | 60.4x | 38.6x | 34.2x |
| PBR | 19.1x | 11.2x | 4.79x | 7.45x | 5.46x | 14.5x | 11.3x | - |
| PEG | - | 1.8x | 3x | -0x | 0.5x | 1x | 0.7x | 2.7x |
| Capitalization / Revenue | 119x | 49.9x | 22.4x | 21x | 11.1x | 22.4x | 16.8x | 17.5x |
| EV / Revenue | 114x | 46.4x | 18.6x | 18.9x | 9.81x | 21.4x | 15.8x | 17.5x |
| EV / EBITDA | -29x | -74.2x | -57.8x | 87.3x | 28.8x | 43.8x | 35.4x | 37.5x |
| EV / EBIT | -26.6x | -65.9x | -49.6x | 106x | 31.1x | 48.1x | 34.3x | 38.3x |
| EV / FCF | -29.7x | -73.5x | -49.8x | 102x | 41.7x | 111x | 55.4x | - |
| FCF Yield | -3.37% | -1.36% | -2.01% | 0.98% | 2.4% | 0.9% | 1.81% | - |
| Dividend per Share 2 | - | - | - | 0.8936 | 1.352 | 0.9586 | 1.466 | - |
| Rate of return | - | - | - | 0.18% | 0.32% | 0.06% | 0.1% | - |
| EPS 2 | -8.773 | -3.932 | -1.568 | 7.214 | 12.25 | 24.83 | 38.85 | 43.81 |
| Distribution rate | - | - | - | 12.4% | 11% | 3.86% | 3.77% | - |
| Net sales 1 | 656.5 | 2,882 | 5,106 | 9,735 | 15,635 | 27,759 | 37,077 | 35,594 |
| EBITDA 1 | -2,595 | -1,800 | -1,645 | 2,104 | 5,327 | 13,602 | 16,574 | 16,591 |
| EBIT 1 | -2,822 | -2,028 | -1,913 | 1,736 | 4,928 | 12,360 | 17,114 | 16,243 |
| Net income 1 | -2,811 | -1,375 | -623.8 | 2,966 | 5,045 | 10,490 | 16,251 | 18,540 |
| Net Debt 1 | -2,917 | -10,211 | -19,582 | -21,000 | -20,406 | -26,524 | -34,728 | - |
| Reference price 2 | 238.02 | 387.49 | 281.07 | 499.59 | 423.70 | 1,500.00 | 1,500.00 | 1,500.00 |
| Nbr of stocks (in thousands) | 327,980 | 371,210 | 407,644 | 409,783 | 410,264 | 414,432 | - | - |
| Announcement Date | 3/2/22 A | 3/1/23 A | 2/27/24 A | 2/26/25 A | 3/3/26 A | - | - | - |
1TWD in Million2TWD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 20.97x | 7.34x | 14.96x | 1.41% | 70.07B | |
| 30.34x | 7.64x | 23.38x | 0.05% | 52.87B | |
| -78.21x | 14.61x | -74.55x | -.--% | 27.02B | |
| 29.96x | 5.86x | 15.52x | -.--% | 23.61B | |
| -14.6x | 5.15x | -6.71x | -.--% | 23.38B | |
| 60.41x | 21.44x | 43.75x | 0.06% | 19.43B | |
| 25.59x | 4.85x | 16.27x | -.--% | 18.75B | |
| -802.92x | 37.67x | -14929.22x | -.--% | 15.85B | |
| 15.89x | 4.68x | 10.93x | -.--% | 12.7B | |
| Average | -79.17x | 12.14x | -1,653.96x | 0.17% | 29.3B | |
| Weighted average by Cap. | -36.21x | 10.37x | -890.90x | 0.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 6446 Stock
- 261280558 Stock
- Valuation PharmaEssentia Corporation
Select your edition
All financial news and data tailored to specific country editions
